retatrutide parkinson disease clinical trial More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Incretin triple agonist retatrutide (LY3437943)

Response rates in the clinical trial were not 100%, and some individuals simply do not show meaningful fat mobilization from this pathway

In Wegovys trials, all participants had excess body weight or obesity

Venkateshappa C, Harish G, Mahadevan A, Bharath MS, Shankar SK (2012) Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: implications for neurodegeneration in Alzheimers disease

At nighttime, lixisenatide increased HR by 2.2 bpm compared with approximately 10 bpm for both liraglutide doses (Table 1)

Buyer Takeaway: Compounded GLP-1 medications are a legal, widely used route for patients who can't access or afford brand-name FDA-approved GLP-1 drugs